Pregabalin for Opiate Withdrawal Syndrome

Status Completed

Clinical Trial Summary

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

Clinical Trial Description

Study design: Single-blind randomized symptom-regulated protocol with an active control. Eighty patients admitted to an inpatient addiction treatment program will be randomly assigned to two groups. The first group (N=40) receives up to 600 mg a day of Pregabalin for six days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine). The second group (N= 40) receives up to 600 micrograms of Clonidine a day as the main treatment along with the same basic and symptomatic regimen. Opiate withdrawal severity, craving, sleep disturbance, anxiety and depression, as well as general clinical impressions and side effects are assessed daily by psychiatrists who are blind to patients' group assignment using internationally validated quantitative psychometric instruments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03017430
Study type	Interventional
Source	St. Petersburg Bekhterev Research Psychoneurological Institute
Contact
Status	Completed
Phase	Phase 4
Start date	January 2014
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04080037` - Assessing Opioid Care Practices Using CPV Patient Simulation Modules	N/A
Completed	`NCT04126083` - Lofexidine for Adults Undergoing Lumbar Spine Surgery	Phase 4
Completed	`NCT04140955` - Opioid Tapering After Spine Surgery	N/A
Not yet recruiting	`NCT03813095` - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction	Phase 2
Completed	`NCT01262092` - Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals	Phase 2
Completed	`NCT04075214` - Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal	N/A
Recruiting	`NCT04325659` - An Innovative Intervention for OUD Treatment	Phase 2/Phase 3
Withdrawn	`NCT03678792` - Comparison of Three Opioid Detoxification Treatment Regimens	Phase 3
Terminated	`NCT04162145` - BRIDGE Device for Treatment of Opioid Withdrawal	N/A
Completed	`NCT04238754` - Oral Cannabidiol for Opioid Withdrawal	Phase 1/Phase 2
Recruiting	`NCT05053503` - Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder	N/A
Recruiting	`NCT05555485` - Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain	N/A
Active, not recruiting	`NCT03485430` - Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up	N/A
Recruiting	`NCT05790551` - Suboxone Dispenser for OUD	N/A
Completed	`NCT03174067` - Buprenorphine in the Emergency Department	Phase 4
Completed	`NCT04731935` - Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal	N/A
Completed	`NCT04470050` - Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal	Phase 1/Phase 2
Not yet recruiting	`NCT06442566` - ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain	Phase 1/Phase 2
Recruiting	`NCT05307458` - Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Completed	`NCT03789214` - Medical Management of Sleep Disturbance During Opioid Tapering	Phase 2